Mutlu Doğan

968 total citations
83 papers, 548 citations indexed

About

Mutlu Doğan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Mutlu Doğan has authored 83 papers receiving a total of 548 indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 16 papers in Pathology and Forensic Medicine. Recurrent topics in Mutlu Doğan's work include Colorectal Cancer Treatments and Studies (12 papers), Cancer Treatment and Pharmacology (12 papers) and Lung Cancer Treatments and Mutations (10 papers). Mutlu Doğan is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Cancer Treatment and Pharmacology (12 papers) and Lung Cancer Treatments and Mutations (10 papers). Mutlu Doğan collaborates with scholars based in Türkiye, United States and Belarus. Mutlu Doğan's co-authors include Nurullah Zengin, Doğan Uncu, Fahriye Tuğba Köş, Esra Karakaş, Öznur Bal, Ahmet Demirkazık, Nebi Serkan Demirci, Nuriye Özdemir, Hakan Akbulut and Umut Demırcı and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Mutlu Doğan

73 papers receiving 541 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mutlu Doğan Türkiye 12 279 133 90 85 74 83 548
Ozan Yazıcı Türkiye 14 328 1.2× 172 1.3× 105 1.2× 80 0.9× 121 1.6× 109 674
Yaşar Yıldız Türkiye 18 381 1.4× 138 1.0× 124 1.4× 107 1.3× 128 1.7× 67 798
Marianne Davies United States 14 482 1.7× 138 1.0× 75 0.8× 46 0.5× 74 1.0× 38 795
Anna Zygogianni Greece 15 212 0.8× 161 1.2× 151 1.7× 109 1.3× 96 1.3× 86 722
Adam Uslu Türkiye 12 156 0.6× 98 0.7× 169 1.9× 92 1.1× 37 0.5× 76 560
Luciano Paladini Brazil 8 213 0.8× 96 0.7× 97 1.1× 38 0.4× 46 0.6× 20 526
Fadi El Karak Lebanon 13 225 0.8× 155 1.2× 78 0.9× 49 0.6× 45 0.6× 51 462
Hüseyin Abalı Türkiye 16 240 0.9× 182 1.4× 126 1.4× 43 0.5× 76 1.0× 62 669
Declan O’Rourke United Kingdom 14 136 0.5× 141 1.1× 95 1.1× 58 0.7× 123 1.7× 37 709
Mehmet Akif Öztürk Türkiye 12 295 1.1× 147 1.1× 123 1.4× 128 1.5× 151 2.0× 40 642

Countries citing papers authored by Mutlu Doğan

Since Specialization
Citations

This map shows the geographic impact of Mutlu Doğan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mutlu Doğan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mutlu Doğan more than expected).

Fields of papers citing papers by Mutlu Doğan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mutlu Doğan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mutlu Doğan. The network helps show where Mutlu Doğan may publish in the future.

Co-authorship network of co-authors of Mutlu Doğan

This figure shows the co-authorship network connecting the top 25 collaborators of Mutlu Doğan. A scholar is included among the top collaborators of Mutlu Doğan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mutlu Doğan. Mutlu Doğan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Karaçin, Cengiz, Zuhat Urakçı, Ali Yılmaz, et al.. (2024). Efficacy and Safety of Bevacizumab in Patients with Low-Grade Serous Ovarian Cancer. Future Oncology. 20(4). 207–214.
2.
Doğan, Mutlu, et al.. (2023). 288P Prognostic factors in nonmetastatic HER2 ‘low’ & HER2 ‘negative’ breast cancer: Single institute experience. Annals of Oncology. 34. S299–S300. 1 indexed citations
3.
Doğan, Mutlu, et al.. (2023). The Potential Prognostic Marker TyG Index Predicts Time to Brain Metastasis at HER2 Positive Breast Cancer. Cancer Management and Research. Volume 15. 311–317. 4 indexed citations
4.
İlhan, Ayşegül, et al.. (2021). The Need for Effective Adjuvant Therapy in Uterine Leiomyosarcoma: A Single-centre Experience. Journal of College of Physicians And Surgeons Pakistan. 31(8). 926–931. 1 indexed citations
5.
Paydaş, Semra, Şahin Laçin, Mutlu Doğan, et al.. (2021). Easier and more explanatory indices by integrating leukocyte lymphocyte ratio (LLR) and prognostic nutritional index (PNI) to IPS systems in cases with classical Hodgkin lymphoma. Leukemia Research. 107. 106586–106586. 9 indexed citations
6.
Paydaş, Semra, Şahin Laçin, Mutlu Doğan, et al.. (2021). IPS-3 Validation in 1012 cases with classical hodgkin lymphoma. Leukemia Research. 102. 106519–106519. 1 indexed citations
7.
Karaçin, Cengiz, Ramazan Acar, Öznur Bal, et al.. (2021). “Swords and Shields” against COVID-19 for patients with cancer at “clean” and “pandemic” hospitals: are we ready for the second wave?. Supportive Care in Cancer. 29(8). 4587–4593. 4 indexed citations
8.
Doğan, Mutlu, Mehmet Artaç, Levent Korkmaz, et al.. (2021). The Relationship Between Plexin C1 Overexpression and Survival in Hepatocellular Carcinoma: a Turkish Oncology Group (TOG) Study. Journal of Gastrointestinal Cancer. 53(2). 356–362. 3 indexed citations
9.
Bal, Öznur, et al.. (2020). Albumin–to–Alkaline Phosphatase Ratio. Pancreas. 50(1). 111–117. 5 indexed citations
10.
Oruç, Zeynep, Kaplan Ma, Çağlayan Geredeli, et al.. (2020). Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study.. PubMed. 24(2). 1876–1883. 2 indexed citations
11.
Bal, Öznur, et al.. (2020). Systemic treatment options for growing teratoma syndrome. Journal of Cancer Research and Therapeutics. 17(1). 75–79.
12.
Yazıcı, Ozan, Mutlu Doğan, Ahmet Demirkazık, et al.. (2020). Osteopontin is a Prognostic Factor in Patients with Advanced Gastric Cancer. Combinatorial Chemistry & High Throughput Screening. 24(8). 1229–1235. 6 indexed citations
13.
Uçar, Gökhan, Yakup Ergün, Öznur Bal, et al.. (2020). Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?. Cureus. 12(9). e10525–e10525. 5 indexed citations
14.
Erdem, Gökmen Umut, Mutlu Doğan, Abdullah Sakin, et al.. (2018). Non-Urothelial Bladder Cancer: Comparison of Clinicopathological and Prognostic Characteristics in Pure Adenocarcinoma and Non-Bilharzial Squamous Cell Carcinoma of the Bladder. Oncology Research and Treatment. 41(4). 220–225. 2 indexed citations
15.
16.
17.
Doğan, Mutlu, et al.. (2016). Oxaliplatin-induced acute thrombocytopenia. Journal of Cancer Research and Therapeutics. 12(2). 509–514. 28 indexed citations
18.
Eralp, Yeşim, Leyla Kılıç, Gül Alço, et al.. (2014). The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience. SHILAP Revista de lepidopterología. 10(4). 209–215. 5 indexed citations
19.
Doğan, Mutlu, Halil Gürhan Karabulut, Ajlan Tükün, et al.. (2012). Relationship Between Antimetabolite Toxicity and Pharmacogenetics in Turkish Cancer Patients. Asian Pacific Journal of Cancer Prevention. 13(4). 1553–1556. 8 indexed citations
20.
Doğan, Mutlu, et al.. (2010). Intestinal malignant melanoma presenting with small bowel invagination: A case report. The Turkish Journal of Gastroenterology. 21(4). 439–442. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ozan Yazıcı Breakdown of academic impact, for papers by Yaşar Yıldız Breakdown of academic impact, for papers by Marianne Davies Breakdown of academic impact, for papers by Anna Zygogianni Breakdown of academic impact, for papers by Adam Uslu Breakdown of academic impact, for papers by Luciano Paladini Breakdown of academic impact, for papers by Fadi El Karak Breakdown of academic impact, for papers by Hüseyin Abalı Breakdown of academic impact, for papers by Declan O’Rourke Breakdown of academic impact, for papers by Mehmet Akif Öztürk
Rankless by CCL
2026